08 · Clinical readouts

Clinical readouts

Erasca says 44% of 25 responded; it’s Phase 1 · No. 052 · · About 2 min read

Bookmarks need a Mind Club sign-in. How sign-in works

Beyond the five things: a Phase 3 survival win for Merck’s TROP2 drug conjugate, a mast cell drug stopped in eczema, a TB regimen with no numbers, and a CAR-T safety signal.

Drug · sponsorSettingResult, as statedLabel
Sacituzumab tirumotecan · MerckGastroesophageal adenocarcinoma after two or more prior lines, randomized, open-label Phase 3 TroFuse-015, 473 patients (NCT06356311)Met its primary endpoint of overall survival against physician’s choice of chemotherapy; missed progression-free survival, a secondary endpoint. No hazard ratio or medians in the release; data to come at a medical meetingClaim
Barzolvolimab · CelldexModerate to severe atopic dermatitis, Phase 2, 131 patientsMissed its week 16 itch primary at both doses (300 mg: −29.2% vs −19.5% on placebo, p=0.187); EASI and IGA did not differ meaningfully. Celldex stopped the program; urticaria Phase 3s continueClaim
AlpE · BioVersysDrug-sensitive pulmonary tuberculosis, Phase 2a ENABLEAll regimens showed bactericidal activity, rising with the ethionamide dose; no values or patient numbers in the releaseClaim
Cilta-cel (BCMA CAR-T)Multiple myeloma, multicenter safety study, Nature MedicineImmune effector cell-associated enterocolitis in 39 of 1,308 recipients, cumulative incidence 3.0% (95% CI 2.1 to 4.1%), median onset 75 daysVerified

Merck release on Business Wire, read through StockTitan (11.20, 6:45 am ET) (opens another website in a new tab); Celldex (11.19) (opens another website in a new tab); BioVersys (11.20) (opens another website in a new tab) Co; Nature Medicine (11.19) (opens another website in a new tab) Peer. PMV Pharma presents pivotal rezatapopt data at ENA at 6:00 am PT on 11.20, after this edition.

RED TEAM

Merck’s release gives no hazard ratio or medians, so the size of the survival gain is unknown, and the trial was open-label. BioVersys’s release gives no numbers, so we cannot judge the size of the effect. The enterocolitis rate comes from a retrospective series and may undercount mild cases. Analysis